Kisspeptin-10 vs Tadalafil Peptide
A side-by-side research comparison of Kisspeptin-10 and Tadalafil Peptide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Kisspeptin-10 | Tadalafil Peptide |
|---|---|---|
| Full name | Kisspeptin-10 (Metastin 45-54) | Tadalafil-Peptide Conjugate (Experimental) |
| Category | Sexual Health | Sexual Health |
| Status | Research compound | Research compound |
| Mechanism | Binds KISS1R on GnRH neurons, stimulating GnRH pulsatile release for LH/FSH secretion. Also enhances limbic sexual arousal circuits. | CPP moiety facilitates targeted PDE5 inhibitor delivery to penile smooth muscle. Local PDE5 inhibition increases cGMP for NO-mediated vasodilation with reduced systemic exposure. |
| Molecular weight | 1,302 Da | ~2,500 Da (conjugate) |
| Half-life | 4-6 min (IV) / 20-30 min (SubQ) | 8-12 hours |
| Bioavailability | High (IV/SubQ) | Targeted (topical/local) |
| Typical dose | 1-10 nmol/kg | 1-5 mg equivalent |
| Frequency | Single dose or daily | As needed |
| Route | IV or Subcutaneous | Topical or local injection |
Kisspeptin-10 reported benefits
- Stimulates GnRH naturally
- Increases LH and testosterone
- Enhances sexual arousal (fMRI data)
- Potential fertility aid
- HPG axis diagnostic tool
Tadalafil Peptide reported benefits
- Targeted PDE5 inhibition
- Reduced systemic side effects
- Potentially faster onset
- Lower dose requirement
Related comparisons
Research and educational reference only. Not medical advice.